Jennison Associates LLC Has $102.76 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Jennison Associates LLC increased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 291.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,998,541 shares of the company's stock after purchasing an additional 2,978,263 shares during the quarter. Jennison Associates LLC owned approximately 4.33% of NewAmsterdam Pharma worth $102,763,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in NAMS. FMR LLC raised its stake in shares of NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company's stock worth $5,485,000 after purchasing an additional 86,712 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in NewAmsterdam Pharma by 1,231.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company's stock worth $3,972,000 after buying an additional 221,305 shares during the last quarter. JPMorgan Chase & Co. raised its position in NewAmsterdam Pharma by 176.9% during the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after acquiring an additional 14,280 shares in the last quarter. State Street Corp lifted its stake in NewAmsterdam Pharma by 168.7% in the third quarter. State Street Corp now owns 37,915 shares of the company's stock valued at $629,000 after acquiring an additional 23,805 shares during the last quarter. Finally, abrdn plc grew its position in shares of NewAmsterdam Pharma by 69.8% in the 3rd quarter. abrdn plc now owns 129,060 shares of the company's stock valued at $2,142,000 after acquiring an additional 53,060 shares during the period. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Trading Down 4.3 %

Shares of NASDAQ:NAMS traded down $0.91 during trading on Friday, reaching $20.19. 305,176 shares of the stock were exchanged, compared to its average volume of 663,693. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The stock has a 50-day moving average price of $23.59 and a 200-day moving average price of $20.06.

Insider Buying and Selling

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the sale, the insider now owns 11,778,760 shares of the company's stock, valued at $295,411,300.80. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 446,730 shares of company stock valued at $11,438,695. Insiders own 19.50% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on NAMS shares. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC restated a "buy" rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank raised their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $41.60.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.